Tag: Bispecific t cell engager

In May 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the immunotherapy **AMG 757**, now known as tarlatamab, for treating extensive-stage small cell lung cancer (SCLC). This approval marked a significant milestone, as treatment options for SCLC that has relapsed after initial chemotherapy have historically been limited.

Tebentafusp was the first-in-class T-cell receptor therapeutic to be approved by the FDA, representing a significant breakthrough in cancer treatment. This innovative immunotherapy, also known by its brand name Kimmtrak, is a targeted therapy for adults with unresectable or metastatic uveal melanoma.